Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

Darunavir/cobicistat is associated with negative outcomes in HIV-negative patients with severe COVID-19 pneumonia

(2021) Jovana Milic et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus–A Possible Reference for Coronavirus Disease‐19 Treatment Option

(2020) Tian‐Tian Yao et al.   JOURNAL OF MEDICAL VIROLOGY

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

(2020) Guangdi Li et al.   NATURE REVIEWS DRUG DISCOVERY

Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms

(2020) Bodee Nutho et al.   BIOCHEMISTRY

Cobicistat: A case of mislabelled drug‐drug interaction risk?

(2020) David M. Burger et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Controversial Relationship between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy

(2020) Augusto Di Castelnuovo et al.   HYPERTENSION

Lack of Antiviral Activity of Darunavir against SARS-CoV-2

(2020) Sandra De Meyer et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach

(2020) Salman Ali Khan et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study

(2020) Augusto Di Castelnuovo et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”

(2020) Laura Ambra Nicolini et al.   Open Forum Infectious Diseases

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19

(2020) Jun Chen et al.   Open Forum Infectious Diseases

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

(2020) Augusto Di Castelnuovo et al.   European Journal of Internal Medicine

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

(2020) Peter W Horby et al.   LANCET

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies

(2020) Augusto Di Castelnuovo et al.   VASCULAR PHARMACOLOGY

Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review

(2020) Betsy Ann Joseph et al.   Expert Review of Anti-Infective Therapy

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat

(2017) Md Amin Hossain et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications

(2016) Catia Marzolini et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Coronaviruses — drug discovery and therapeutic options

(2016) Alimuddin Zumla et al.   NATURE REVIEWS DRUG DISCOVERY

Protease inhibitors targeting coronavirus and filovirus entry

(2015) Yanchen Zhou et al.   ANTIVIRAL RESEARCH

Methods for Constructing and Assessing Propensity Scores

(2014) Melissa M. Garrido et al.   HEALTH SERVICES RESEARCH

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

(2012) C Orkin et al.   HIV MEDICINE

Protease Inhibitor–Associated QT Interval Prolongation

(2011) Kimberley Hunt et al.   ANNALS OF PHARMACOTHERAPY